The chemical industry is a crucial part of the global economy, supporting the food supply, healthcare, and other consumer needs. However, overuse of toxic halogenated hydrocarbons (a.k.a. organohalides) is causing potentially avoidable health care costs of US$340 billion annually in the U.S. and €150 billion in the European Union. In addition, lawsuits continue to generate billion-dollar settlements and multiple bankruptcies of chemical giants like Dupont. We here put forth a novel economic incentive, termed the XXXX (name of framework withheld till publication is processed), to facilitate a cost- and market-driven transition away from organohalide chemistries. By placing a health premium on newly formed carbon-halogen bonds, whether domestically produced or imported, this economic incentive fosters the avoidance of future production of persistent, bioaccumulative, and toxic (PBT) organohalides, thereby encouraging the use of safer, alternative chemicals. In contrast to currently employed policy solutions, which are often slow and reactive, our policy offers a novel, proactive, and non-limiting path toward future use of greener chemicals. While safeguarding the interests of both the chemical industry and the general public, this policy also promotes innovation and promotes green chemistry. Since this novel policy approach foregoes new chemical regulations and bans, it is non-disruptive to industry operations, supportive of consumer needs, and it aligns with the United Nations sustainable development goals. Its adoption promises a quick, pragmatic, and practical escape from the present realities of risky chemical designs, slow regulatory actions, regrettable substitutions of one toxic organohalide with a structurally related risky chemical cousin, and the resultant billion-dollar lawsuits and settlements that have left the backbone and motor of human progress exposed and vulnerable: the modern chemical industrial complex.